NCT06911606View on ClinicalTrials.gov

Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC)

PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

May 22, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
SCLC, Limited Stage
Interventions
DRUG

4 cycles of Serplulimab combined with etoposide and carboplatin or cisplatin

After 4 cycles of Serplulimab combined with etoposide and carboplatin or cisplatin then MDT determines surgery or radical radiotherapy

Trial Locations (1)

Unknown

RECRUITING

Guangdong Provincial People's Hospital, Guangzhou

All Listed Sponsors
collaborator

Liaoning Cancer Hospital & Institute

OTHER

collaborator

Guangzhou No.12 People's Hospital

OTHER_GOV

collaborator

Second Xiangya Hospital of Central South University

OTHER

lead

Guangdong Provincial People's Hospital

OTHER